1 min read
Lexeo Trial Data Leads Raymond James and Cantor Fitzgerald to Raise Targets
The target changes followed interim data from a Phase I/II trial of LX2020 for PKP2 arrhythmogenic cardiomyopathy. Raymond James views Lexeo as a strong buy.

Raymond James and Cantor Fitzgerald raised their price targets for Lexeo Therapeutics (LXEO) after interim data from a Phase I/II trial of LX2020 for PKP2 arrhythmogenic cardiomyopathy.
Raymond James views Lexeo as a strong buy.